KRFK (TFA)

KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach[1].

Product Specifications

UNSPSC

12352209

Target

TGF-β Receptor

Type

Peptides

Related Pathways

TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/krfk-tfa.html

Purity

99.90

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCCN)C(O)=O)=O)=O)[C@H](CCCCN)N.OC(C(F)(F)F)=O.[x]

Molecular Formula

C27H47N9O5.xC2HF3O2

Molecular Weight

577.73 (free base)

References & Citations

[1]Soriano-Romaní L, et al. Topical Application of TGF-β-Activating Peptide, KRFK, Prevents Inflammatory Manifestations in the TSP-1-Deficient Mouse Model of Chronic Ocular Inflammation. Int J Mol Sci. 2018 Dec 20;20 (1) :9.